Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals



Availability: In stock

Special Price $ 160

BRAND : MyDekla
INGREDIENT : HepatitisC-Mylan-Daclatasvir-60mg-Mydekla
COUNT : 28 Tablets

Description of MyDekla

Generic: Daclatasvir Brand: Mydekla Strength of the content: 60mg Mfg: Mylan Primary use: for chronic hepatitis C viral infection (HCV) Mydekla Description: Mydekla is classified as anti-viral drug called hepatitis C virus NS5A Mydekla is a phosphoprotein that acts as leading role in hepatitis C multiplication. Mydekla is used along with other antiviral medicines like Sofosbuvir Mydekla, which inhibits the NS5A replication complex. Finally that Daclatasvir prohibits viral RNA multiplication.

Pharmacology of MyDekla

NS5A is an unstructured viral polyprotein; it acts as replicating complex in viral RNA Mydekla (Daclatasvir) act as hepatitis C NS5A inhibitor. This NS5A has ability to bind to HCV RNA, undergone multiplication. Mydekla interfere with the activity of polyprotein and block the function of new HCV multiplication synthesis and virion assembly or secretion Mydekla worked by blocking the viral replication leads to chain termination. Pharmacokinetic: Absorption: The plasma peak concentration of Mydekla occurred within 2 hours. The absolute bioavailability of Mydekla is 67% Distribution: The human plasma protein bound with Mydekla in affected persons is nearly 99% The volume of distribution is 47L. Metabolism: Mydekla is a substrate of CYP3A enzymes which is required for its metabolism. The distribution of drug in plasma is in unchanged form Excretion: Among 88% of total dose of Mydekla is eliminated through bile and feces in 53% as an unchanged form; 6.6% in urine as unchanged form The terminal half life period of Mydekla is around 12 to 15 hours.

Indication of MyDekla

Mydekla is an anti-viral drug, useful for the treatment of chronic hepatitis C viral infection by inhibiting the replication of hepatitis C virus Mydekla is involved in the treatment of genotype III advanced hepatitis C virus in adults without cirrhosis Generally Mydekla tablets are not used alone, it may combined with other anti-viral medicines like Sofosbuvir, interferon and ribavirin

Dose & Dosage's of MyDekla

Mydekla is usually used in the condition like hepatitis C virus infection; Mydekla with Sofosbuvir in genotype I and III infection Genotype I: Without cirrhosis or with compensated cirrhosis (child Pugh A) 60mg of Mydekla with 400mg of Sofosbuvir taken as orally for 12 weeks as single dose In decompensated cirrhosis: Mydekla 60mg with 400mg of Sofosbuvir and ribavirin should be taken as orally for 12 weeks as single dose Genotype III: Without cirrhosis: 60mg Mydekla plus 400mg Sofosbuvir for 12 weeks taken as single dose orally In decompensated cirrhosis: Mydekla 60mg with 400mg of Sofosbuvir and ribavirin should be taken as orally for 12 weeks as single dose Ribavirin dosing: HCV genotype I or III with decompensated cirrhosis or post transplantation: 600mg of ribavirin initial dose taken as single use, increasing up to 1000mg/day if tolerated HCV genotype III with compensated cirrhosis: Based on weight <75kg: 1000mg/day ≥75kg: 1200mg/day It should be taken as twice daily with food In pediatric: <18 years the safety and efficacy of the tablet Mydekla has not been established

Side Effects of MyDekla

The list of common side effects while receiving Mydekla tablets; Headache Nausea Fatigue Insomnia Low levels of iron in the blood Drowsiness Dizziness, rash Constipation Vomiting Hair loss Some serious side effects; Sloe heart beats Chest pain Difficulty in moving Shortness of breath Memory problems Loss or gaining of weight Loss of appetite Muscle aches Joint pain

Contraindication of MyDekla

Mydekla Concomitant with strong CYP3A inducers (carbamazepine, phenytoin, rifampin) cause some hypersensitivity reaction When used in combination with ribavirin, contraindicated to pregnancy condition Anaphylactic reaction occurs

Drug Interaction of MyDekla

While some concomitant drugs may cause interactions Amiodarone: concomitant with Mydekla causes bradycardia Aprepitant: increase the serum concentration of CYP3A4 substrates Some list of drugs; Asunaprevir, betrixaban, bilastine, buprenorphine CYP3A4 inducers (strong): decrease the serum concentration of Mydekla CYP3A4 inhibitors: decrease the metabolism of CYP3A4 substrates Warfarin: Mydekla increase the anti-coagulant activity

Precaution of MyDekla

While combining with amiodarone care should be taken because Mydekla causes increase the bradycardia effects of amiodarone Care should be taken while using Mydekla tablets in patients having conditions like: Cardiovascular disease patient Hepatic impairment Hepatitis B reactivation occurs after discontinuation Before going to start the treatment, if patient having the following conditions they must seek medical advice; Liver problems or liver transplant Heart problems Pregnant condition Breast feeding Trying to become pregnant

Usage & Safety profile of MyDekla Pregnancy & Lactation

While concomitant Mydekla with ribavirin in advanced stage; it is not recommended in pregnancy condition and breast feeding Ribavirin pregnancy category: X Ribavirin causes fetal death

Storage of MyDekla

Mydekla tablet container should be stored at 25oC (77oF); excursion permitted between 15oC and 30oC (59oF and 86oF) Keep away the container from moisture, heat, and light